Understand CJC-1295 DAC 5mg quantities, actual human study exposure, concentration calculations, hormone pulsatility, handling, and unresolved safety.
CJC-1295 DAC 5mg describes a nominal 5 mg vial amount of a long-acting GHRH analog. The approximately 6–8-day half-life was measured in healthy human adults given the DAC compound; the label amount is neither proof of content nor a recommended human dose. CJC-1295 has no FDA-approved human indication.
What "DAC" Means in a CJC-1295 DAC 5mg Vial
CJC-1295 is a synthetic 30-amino-acid analog of GHRH. The DAC is a maleimide group that forms a covalent bond with serum albumin after administration, and that bond shields the peptide from the enzymes that normally break down GHRH within minutes.
Sustained stimulation does not mean GH pulses disappear. Ionescu and Frohman’s human sampling study found increased trough and mean GH with preserved pulse frequency and magnitude one week after CJC-1295 DAC. Calling the response a flat, nonpulsatile “GH bleed” misrepresents that result.
A half-life describes an approximately 50% concentration decline under the studied conditions, not the time until all drug is gone or every adverse effect resolves. Repeat exposure, assay detection limits, and individual pharmacokinetics prevent a single “fully cleared by” date.
CJC-1295 With DAC vs CJC-1295 Without DAC
The material marketed as CJC-1295 no DAC or Mod GRF (1-29) lacks the albumin-binding modification and is distinct from the DAC compound studied in the cited human trials. FDA’s assessment cautions against transferring the DAC pharmacological profile to non-DAC forms; it does not establish a universal 30-minute human half-life or a daily regimen for all such products.
| Feature | DAC compound | No-DAC material |
|---|---|---|
| Half-life | 5.8–8.1 days in healthy adults | Not supplied by the DAC trials |
| Albumin binding | Yes (DAC modification) | No |
| GH response | Higher trough/mean GH; pulses preserved | No head-to-head safety advantage established |
| Exposure schedule | Single and short repeat-dose trials | No approved personal regimen supplied |
| Vial size | Nominal amount requiring verification | Package size is not a dose |
| Combination evidence | The cited DAC trials did not validate a retail stack | Own constituent and compatibility data needed |
A widely repeated 30-minute value cannot be used here as a universal human estimate for every no-DAC product or as justification for daily personal use.
After a single administration in that study, mean GH increased about 2–10-fold for at least six days, while mean IGF-1 increased about 1.5–3-fold for nine to eleven days. These are group biomarker findings, not proof of muscle gain, fat loss, better sleep, or long-term safety.
How to Reconstitute a 5mg Vial
For laboratory reconstitution, use the exact material’s validated method, compatible diluent, and container capacity. Bacteriostatic water is not a universal requirement: its product labeling describes preserved water, but does not establish compatibility or a storage life for CJC-1295 DAC.
- Check the preparation temperature specified by the validated method, rather than assigning a universal 10–15-minute warming period.
- Swab both stoppers with an alcohol pad and let them air dry.
- Follow the method’s addition procedure using compatible, appropriately specified materials.
- Use validated mixing conditions; avoid claiming that all shaking necessarily damages the peptide.
- Appearance is only a limited handling observation. Unexpected particles or discoloration warrant stopping the laboratory procedure and checking the specification; a clear solution cannot establish identity, potency, endotoxin level, or sterility.
Benzyl-alcohol-preserved water can limit bacterial growth under its labeled conditions, but does not establish this peptide’s compatibility, sterility after preparation, or use-by time.
| Final volume for nominal 5 mg | Calculated concentration | Peptide in 0.01 mL (one U-100 unit marking) |
|---|---|---|
| 1 mL | 5 mg/mL | 50 mcg |
| 2 mL | 2.5 mg/mL | 25 mcg |
| 3 mL | About 1.67 mg/mL | About 16.7 mcg |
| 5 mL | 1 mg/mL | 10 mcg |
Dosing Discussed in Published Research
The 2006 randomized, placebo-controlled trials followed healthy adults for 28 or 49 days. Single-dose cohorts received 30, 60, 125, or 250 mcg/kg; the repeat-dose study used two or three administrations at weekly or biweekly intervals. These were monitored research protocols, not an approved personal dosing schedule.
The multiple-dose study explored two or three administrations at weekly or biweekly intervals and found cumulative effects on IGF-1. This was short controlled research, not a validated ongoing schedule for a nominal 5 mg retail vial.
The original doses were expressed in mcg/kg. Both mcg and mg are mass units; the long half-life does not require one unit system rather than the other.
No-DAC exposure needs separate evidence, not an automatic assumption of smaller and more frequent human amounts.
CJC-1295 and Ipamorelin Research Stacks
Ipamorelin acts through the ghrelin receptor pathway, whereas CJC-1295 acts through the GHRH receptor pathway. Different mechanisms do not establish a safe combination dose, compatibility in one vial, or superior sleep, recovery, or body composition. The cited DAC trials did not validate the online CJC-1295/ipamorelin schedules.
A cjc 1295 no dac ipamorelin reddit search should be traced to original dated posts. No thread collection is supplied here to establish abundant reports or a consensus.
The DAC trials do not establish a clinically validated combined regimen, regardless of whether suppliers package the ingredients together.
Storage, Stability, and Safety Notes
Storage temperature and use-by time depend on the peptide formulation, solvent, concentration, container, and validated stability data. There is no universal “refrigerate for four weeks” or “freeze at −20°C” rule for every retail CJC-1295 vial. CDC’s opened multidose-vial guidance is not evidence that a newly mixed peptide remains chemically stable for 28 days.
Aliquoting and freeze-thaw limits are formulation-specific. A larger vial does not automatically require a particular freezing procedure.
The short human studies reported injection-site reactions, flushing or warmth, headache, and gastrointestinal symptoms. FDA also identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and notes limited clinical data and impurity/immunogenicity concerns. Neither a tolerable first exposure nor a normal blood test establishes long-term safety.
CJC-1295 has no FDA-approved human indication and is included in WADA’s 2026 list as prohibited in and out of competition.
Anyone weighing peptide use should discuss it with a licensed healthcare professional. This article is informational and does not endorse human use of any research peptide. Related research also covers CJC-1295 DAC 5mg: Peptide Vial Guide for Researchers.
Frequently Asked Questions
Is CJC-1295 DAC 5mg approved for human use in the United States?
No FDA-approved CJC-1295 human indication is established. A nominal 5 mg vial is not an approved medicine or a recommended dose. CJC-1295 is also explicitly prohibited in and out of competition under the 2026 WADA list for athletes subject to those rules.
How do you reconstitute a CJC-1295 DAC 5mg vial?
Use the exact formulation’s validated laboratory method, compatible diluent, and specified final volume. Record identity, lot, solvent, concentration, and date. A clear solution is not proof of sterility or potency, and preserved water does not establish peptide stability or suitability for human use.
How long does CJC-1295 with DAC stay in your system?
Approximately six to eight days is the reported human DAC half-life, not the time until complete clearance. A single trial administration raised mean GH for at least six days and IGF-1 for nine to eleven days. These values do not establish a washout, testing, or redosing interval for personal use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.